{"id":"NCT02451943","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-14","primaryCompletion":"2018-12-05","completion":"2024-06-27","firstPosted":"2015-05-22","resultsPosted":"2019-12-17","lastUpdate":"2025-07-15"},"enrollment":509,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Soft Tissue Sarcoma"],"interventions":[{"type":"DRUG","name":"Olaratumab","otherNames":["LY3012207"]},{"type":"DRUG","name":"Doxorubicin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Doxorubicin + Olaratumab","type":"EXPERIMENTAL"},{"label":"Doxorubicin + Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main purpose of this study is to evaluate the efficacy of the combination of doxorubicin plus the study drug known as olaratumab versus doxorubicin plus placebo in participants with advanced or metastatic soft tissue sarcoma.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Randomization to Date of Death Due to Any Cause (Up to 35.8 Months)","effectByArm":[{"arm":"Doxorubicin + Olaratumab","deltaMin":20.37,"sd":null},{"arm":"Doxorubicin + Placebo","deltaMin":19.75,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.6945"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":10},"locations":{"siteCount":114,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Denmark","Finland","France","Germany","Hungary","Israel","Italy","Japan","Mexico","Netherlands","Poland","Russia","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["33632930","32259228","28447475"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/1kxWhoB2GsgKesCo08Gmim"]},"adverseEventsSummary":{"seriousAny":{"events":105,"n":257},"commonTop":["Nausea","Fatigue","Alopecia","Anaemia","Neutrophil count decreased"]}}